Comparative antiatherogenic effects of intravenous AAV8- and AAV2-mediated ApoA-IMilano gene transfer in hypercholesterolemic mice

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 20, Issue 1, 2015, Pages 66-75

  Tian, Fang ^a   Wang, Lai ^a   Arias, Ana ^a   Yang, Mingjie ^a   Sharifi, Behrooz G ^a   Shah, Prediman K ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Adeno associated virus; Apolipoprotein A IMilano; Atherosclerosis; Gene therapy

Indexed keywords

ADENO ASSOCIATED VIRUS 2 VECTOR; ADENO ASSOCIATED VIRUS 8 VECTOR; ADENOVIRUS VECTOR; APOLIPOPROTEIN A1; APOLIPOPROTEIN A1 MILANO; ARGININE; CYSTEINE; UNCLASSIFIED DRUG; APOLIPOPROTEIN A;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS 2; ADENO ASSOCIATED VIRUS 8; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; AORTA SINUS; ARTICLE; BRACHIOCEPHALIC TRUNK; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; GENE EXPRESSION; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; QUALITATIVE ANALYSIS; RNA ANALYSIS; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT; WILD TYPE; ADMINISTRATION AND DOSAGE; ANIMAL; ATHEROSCLEROSIS; COMPARATIVE STUDY; DEPENDOPARVOVIRUS; FEMALE; GENE TRANSFER; GENE VECTOR; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; KNOCKOUT MOUSE; MALE;

ADMINISTRATION, INTRAVENOUS; ANIMALS; APOLIPOPROTEINS A; ATHEROSCLEROSIS; DEPENDOVIRUS; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HYPERCHOLESTEROLEMIA; MALE; MICE; MICE, KNOCKOUT;

EID: 84916622931     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248414530041     Document Type: Article

References (22)

1. Franceschini G, Sirtori CR, Capurso A II, Weisgraber KH, Mahley RW. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest. 1980;66(5):892-900.
2. Weisgraber KH, Bersot TP, Mahley RW, Franceschini G, Sirtori CR. A-Imilano apoprotein. Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins. J Clin Invest. 1980;66(5):901-907.
3. Sirtori CR, Calabresi L, Franceschini G, et al. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation. 2001;103(15):1949-1954.
4. Gomaraschi M, Baldassarre D, Amato M, et al. Normal vascular function despite low levels of high-density lipoprotein cholesterol in carriers of the apolipoprotein A-I(Milano) mutant. Circulation. 2007;116(19):2165-2172.
5. Wang L, Sharifi BG, Pan T, Song L, Yukht A, Shah PK. Bone marrow transplantation shows superior atheroprotective effects of gene therapy with apolipoprotein A-I Milano compared with wild-type apolipoprotein A-I in hyperlipidemic mice. J Am Coll Cardiol. 2006;48(7):1459-1468.
6. Franceschini G, Vecchio G, Gianfranceschi G, Magani D, Sirtori CR. Apolipoprotein AIMilano. Accelerated binding and dissociation from lipids of a human apolipoprotein variant. J Biol Chem. 1985;260(30):16321-16325.
7. Bielicki JK, Oda MN. Apolipoprotein A-I(Milano) and apolipoprotein A-I(Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry. 2002;41(6):2089-2096.
8. Feng Y, Van Craeyveld E, Jacobs F, Lievens J, Snoeys J, De Geest B. Wild-type apo A-I and apo A-I(Milano) gene transfer reduce native and transplant arteriosclerosis to a similar extent. J Mol Med. 2009;87(3):287-297.
9. Lebherz C, Sanmiguel J, Wilson JM, Rader DJ. Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent. Cardiovasc Diabetol. 2007;6:15.
10. Ameli S, Hultgardh-Nilsson A, Cercek B, et al. Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation. 1994;90(4):1935-1941.
11. Shah PK, Nilsson J, Kaul S, et al. Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation . 1998;97(8):780-785.
12. Shah PK, Yano J, Reyes O, et al. High-dose recombinant apolipoprotein A-IMilano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice; potential implications for acute plaque stabilization. Circulation. 2001;103(25):3047-3050.
13. Kaul S, Coin B, Hedayiti A, et al. Rapid reversal of endothelial dysfunction in hypercholesterolemic apolipoprotein E-null mice by recombinant apolipoprotein A-I(Milano)-phospholipid complex. J Am Coll Cardiol. 2004;44(6):1311-1319.
14. Ibanez B, Vilahur G, Cimmino G, et al. Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis. J Am Coll Cardiol. 2008;51(11):1104-1109.
15. Parolini C, Marchesi M, Lorenzon P, et al. Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-I Milano/1-palmitoyl-2-oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques: in vivo assessment by intravascular ultrasound and magnetic resonance imaging. J Am Coll Cardiol. 2008;51(11):1098-1103.
16. Reardon CA, Blachowicz L, Lukens J, Nissenbaum M, Getz GS. Genetic background selectively influences innominate artery atherosclerosis: immune system deficiency as a probe. Arterioscler Thromb Vasc Biol. 2003;23(8):1449-1454.
17. Shah PK. Evolving concepts on benefits and risks associated with therapeutic strategies to raise HDL. Curr Opin Cardiol. 2010;25(6):603-608.
18. Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet. 2000;24(3):257-261.
19. Sharifi BG, Wu K, Wang L, Ong JM, Zhou X, Shah PK. AAV serotype-dependent apolipoprotein A-I Milano gene expression. Atherosclerosis. 2005;181(2):261-269.
20. Wu KJ, Fu MJ, Radparvar K, Sharifi BG, Chatterjee S, Shah PK. The tail vein infusion is a more efficient delivery route than intramuscular injection for rAAV2-mediated Apo A-IMilano gene transfer. Mol Ther. 2002;5(5):145.
21. Linton MF, Atkinson JB, Fazio S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science. 1995;267(5200):1034-1037.
22. Cimmino G, Giannarelli C, Chen W, et al. Adeno-associated virus serotype 8 ApoA-I gene transfer reduces progression of atherosclerosis in ApoE-KO mice: comparison of intramuscular and intravenous administration. J Cardiovasc Pharmacol. 2011;57(3):325-333.